Clinical Course of Two Children with Unstable Hemoglobins: The Effect of Hydroxyurea Therapy.
Case reports on the effect of hydroxyurea (HU) therapy for unstable hemoglobins (Hbs) are sparse; only three adult cases have been reported. We report for the first time on the effect of HU therapy in children carrying unstable Hbs. The first case concerns a female child with a familial history of chronic hemolytic anemia. She was diagnosed with Hb Volga (HBB: c.83C>A) at the age of 7 months. At age 6, treatment options were reconsidered due to increasing fatigue and decreasing Hb concentration. The second case also concerns a female child with chronic hemolytic anemia and icterus since the age of 5. She was diagnosed with Hb Köln (HBB: c.295G>A) at the age of 9. At age 10, treatment options were reconsidered due to decreased general condition and poor school performance. Both children were started on HU therapy. The child with Hb Volga showed reduced clinical symptoms and increased average Hb concentrations. She has been on HU therapy for over 7 years at preparation of this manuscript. The child with Hb Köln showed decreasing Hb concentrations upon start of therapy; clinical symptoms did not improve. Therapy was discontinued after 3½ months. The Hb Volga case report suggests that HU therapy could improve clinical symptoms in some patients with unstable Hbs. Based on these and previously published cases, it was speculated that response can be predicted by the percentage of Hb F and reticulocyte counts.
a Department of Laboratory Medicine, Department of Hematology , University Medical Center Groningen (UMCG) , the Netherlands.
Harriët M
HM
Loovers
b Paediatric Hematology and Oncology , Beatrix Children's Hospital, University Medical Center Groningen , the Netherlands.
Nienke
N
Tamminga
a Department of Laboratory Medicine, Department of Hematology , University Medical Center Groningen (UMCG) , the Netherlands.
André B
AB
Mulder
b Paediatric Hematology and Oncology , Beatrix Children's Hospital, University Medical Center Groningen , the Netherlands.
Rienk Y J
RY
Tamminga
D000743:Anemia, Hemolytic; D002648:Child; D002675:Child, Preschool; D005260:Female; D005319:Fetal Hemoglobin / Q000032:analysis; D006455:Hemoglobins, Abnormal / Q000187:drug effects*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D007223:Infant; D011379:Prognosis; D017701:Reticulocyte Count; D016896:Treatment Outcome
D006455:Hemoglobins, Abnormal; C045643:hemoglobin Volga; D005319:Fetal Hemoglobin; C034409:hemoglobin Koln; D006918:Hydroxyurea
Hb Köln; Hb Volga; Hemoglobinopathy; hydroxyurea (HU); pediatric; unstable hemoglobin